Bromazepam: Difference between revisions
No edit summary |
No edit summary |
||
| Line 39: | Line 39: | ||
|}'''Bromazepam''' (Compendium®, Creosedin®, Durazanil®, Lectopam®, Lexaurin®, Lexomil®, Lexotan®, Lexotanil®, Normoc®).{{ref|BrandNames}} Bromazepam is a Schedule IV drug under the [[Convention on Psychotropic Substances]].{{ref|schedule4}} |
|}'''Bromazepam''' (Compendium®, Creosedin®, Durazanil®, Lectopam®, Lexaurin®, Lexomil®, Lexotan®, Lexotanil®, Normoc®).{{ref|BrandNames}} Bromazepam is a Schedule IV drug under the [[Convention on Psychotropic Substances]].{{ref|schedule4}} |
||
Bromazepam is a [[sedative]]-[[hypnotic]] [[anxiolytic]] of the [[benzodiazepine]] class. Its molecular structure is composed of a [[diazepine]] connected to two [[benzene]] rings, one of which has a [[bromine]] atom attached to it.{{ref|bromazepamstructure}} It is a [[1,4-benzodiazepine]], which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions. |
Bromazepam is a [[sedative]]-[[hypnotic]] [[anxiolytic]] of the [[benzodiazepine]] class. Its molecular structure is composed of a [[diazepine]] connected to two [[benzene]] rings, one of which has a [[bromine]] atom attached to it.{{ref|bromazepamstructure}} It is a [[benzodiazepine|1,4-benzodiazepine]], which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions. |
||
==Metabolism== |
==Metabolism== |
||
Bromazepam is reported to be metabolized by the cytochrome P(450) ([[CYP]]) hepatic enzymes. In 2003, Oda et al reported that CYP3A4 was not the one, seeing as [[itraconazole]], an inhibitor of CYP3A4, did not effect its metabolism.{{ref|itraconazole}} [[Fluvoxamine]], an inhibitor of CYP1A2, CYP3A4, and CYP2D6 in that order, does.{{ref|fluvoxamine}} |
Bromazepam is reported to be metabolized by the cytochrome P(450) ([[CYP]]) hepatic enzymes. In 2003, Oda et al reported that CYP3A4 was not the one, seeing as [[itraconazole]], an inhibitor of CYP3A4, did not effect its metabolism.{{ref|itraconazole}} [[Fluvoxamine]], an inhibitor of CYP1A2, CYP3A4, and CYP2D6 in that order, does.{{ref|fluvoxamine}} |
||
Revision as of 06:13, 1 August 2005
|
Bromazepam chemical structure | |
| 7-Bromo-2,3-dihydro-5-(2-pyridinyl)-1H-1,4-benzodiazepin-2-one | |
| CAS number 1812-30-2 |
ATC code N05BA08 |
| Chemical formula | C14H10BrN3O |
| Molecular weight | 316.2 |
| Bioavailability | 84% |
| Metabolism | hepatic |
| Elimination half life | 8-28 hours |
| Excretion | urinary |
| Pregnancy category | ? |
| Legal status | Schedule IV Drug |
| Routes of Administration | oral, rectal, |
Bromazepam (Compendium®, Creosedin®, Durazanil®, Lectopam®, Lexaurin®, Lexomil®, Lexotan®, Lexotanil®, Normoc®).[1] Bromazepam is a Schedule IV drug under the Convention on Psychotropic Substances.[2]
Bromazepam is a sedative-hypnotic anxiolytic of the benzodiazepine class. Its molecular structure is composed of a diazepine connected to two benzene rings, one of which has a bromine atom attached to it.[3] It is a 1,4-benzodiazepine, which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions.
Metabolism
Bromazepam is reported to be metabolized by the cytochrome P(450) (CYP) hepatic enzymes. In 2003, Oda et al reported that CYP3A4 was not the one, seeing as itraconazole, an inhibitor of CYP3A4, did not effect its metabolism.[4] Fluvoxamine, an inhibitor of CYP1A2, CYP3A4, and CYP2D6 in that order, does.[5]
Special Populations
According to Ochs et al, the elimination half-life, peak serum concentration, and serum free fraction are significantly elevated and the oral clearance and volume of distribution significantly lowered in elderly subjects.[6]
Availabity
Bromazepam is available in Canada, Germany, and the United Kingdom (before it was discontinued).
References
- ^ PubChem Substance: Bromazepam
- ^ List of psychotropic substances under international control.
- ^ Eutimia.com: Bromazepam
- ^ Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. European Journal of Clinical Pharmacology. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27.
- ^ van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics. 1995;29 Suppl 1:1-9.
- ^ Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |